Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06292013 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06292013 · ClinicalTrials.gov record · last posted 2026-08-24

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

StatusActive, Not Recruiting
PhasePhase 3
Started2024-03-05
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin). Approximately 1700 additional participants will be enrolled in an addendum to explore Lp(a) lowering with an alternative dosing schema.

Protocol amendment history 1 change detected by DataLookout

2026-08-25
Trial sites reduced: 931 → 928 locations
Trial Details
NCT Number NCT06292013
Lead Sponsor Eli Lilly and Company
Conditions Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Enrollment 17,300 participants
Start Date 2024-03-05
Primary Completion 2029-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-24